SGS Opens Central & Eastern Europe Offices for Clinical Trial Management.
Geneva, Switzerland-April 25, 2008-As a further step in the initiative to expand its Global Clinical Development (GCD) services, SGS Life Science Services has opened three new offices in Poland, Czech Republic, and Romania. The offices located in Prague, Warsaw, and Bucharest, respectively, will provide services for clinical trial monitoring, study feasibility, and site selection, as well as support the regulatory aspects in these countries.
“The opening of the new offices addresses the request of many of our sponsors to conduct trials in Central and Eastern Europe in order to benefit from the vast pool of treatment naïve patients, faster enrolment times, and the cost benefits these countries offer,” said Luc Braeken, vice president of global clinical development. “Highly qualified and motivated investigators, low drop out rates of enrolled patients, and the high quality of the clinical data are additional advantages of conducting trials in Central and Eastern Europe.”
The offices are staffed with highly knowledgeable teams with broad experience in conducting clinical trials in the pharmaceutical and CRO industry as well as in academia. Lead by seasoned MDs, the teams cover a wide range of therapeutic areas with special emphasis in CNS, infectious disease, and cardiovascular disease, SGS’ areas of core expertise.Complementary services including project management, data management and statistics, regulatory affairs, and medical affairs will be provided from SGS’ main office for GCD in Belgium with more than 400 people.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
Merck Stops HYPERION Trial for Winrevair in PAH Following Positive ZENITH Trial Results
January 30th 2025The Phase III HYPERION trial was stopped early after strong positive interim results from the ZENITH trial demonstrated the efficacy of Winrevair (sotatercept-csrk) in treating pulmonary arterial hypertension, making it unethical to continue.